Mitigating GI risks associated with the use of NSAIDs

Pain Medicine (United States)

Volumn 14, Issue SUPPL1, 2013, Pages

  Momeni, Mahnaz ^a   Katz, James D ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Anti Inflammatory; Gastrointestinal; NSAIDs

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HUMAN; IATROGENIC DISEASE; META ANALYSIS (TOPIC); MORTALITY; PEPTIC ULCER; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECONDARY PREVENTION; STOMACH PROTECTION; TREATMENT RESPONSE;

ANTI-INFLAMMATORY; GASTROINTESTINAL; NSAIDS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; HISTAMINE H2 ANTAGONISTS; HUMANS; MISOPROSTOL; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84890873831     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12225     Document Type: Article

References (37)

1. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;56:18-24.
2. Aalykke C, Lauritsen K. Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001;15:705-722.
3. Wolfe M, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;40:1888-1899.
4. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120(3):594-606.
5. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years. Gastroenterology 1997;112(3):1000-1016.
6. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34, 701 arthritis patients. Aliment Pharmacol Ther 2010;32(10):1240-1248.
7. Graham DY. Ulcer complications and their nonoperative treatment. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease. Pathophysiology, Diagnosis and Management, 5th edition. Philadelphia, PA: WB Saunders Co; 1993:698-712.
8. Graham DY, Lew GM, Klein PD, etal. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116:705-708.
9. Leontiadis GI, Sreedharan A, Dorward S, etal. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007;11:1-164.
10. Graham DY, Lidsky MD, Cox AM, etal. Long-term nonsteroidal anti-inflammatory drug use and Helicobacter pylori infection. Gastroenterology 1991;100:1653-1657.
11. Labenz J, Blum AL, Bolten WW, etal. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients; a randomized, double blind, placebo controlled trial. Gut 2002;51:329-335.
12. Lai KC, Lam SK, Chu KM, etal. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033-2038.
13. Chan FK, Chung SC, Suen BY, etal. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-973.
14. Hawkey CJ, Tulassay Z, Szczepanski L, etal. Randomized controlled trial of Helicobacter pylori eradication in patients on nonsteroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998;352:1016-1021.
15. Silverstein FE, Graham DY, Senior JR, etal. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123(4):241-249.
16. Raskin JB, White RH, Jackson JE, etal. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens. Ann Intern Med 1995;123(5):344-350.
17. Graham DY, Agrawal NM, Campbell DR, etal. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;162(2):169-175.
18. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996;156(20):2321-2322.
19. Scheiman JM, Yeomans ND, Talley NJ, etal. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101:701-710.
20. Lanas A, Garcia-Rodriguez LA, Arroyo MT, etal. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507-515.
21. Regula J, Butruk E, Dekkers CP, etal. Prevention of NSAID-associated gastrointestinal lesions: A comparison study pantoprazole vs omeprazole. Am J Gastroenterol 2006;101:1747-1755.
22. Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastro-protective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology 2008;134:937-944.
23. Raskin JB, White RH, Jaszewski R, etal. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double-blind, multicenter study. Am J Gastroenterol 1996;91:223-227.
24. Taha AS, Hudson N, Hawkey CJ, etal. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334(22):1435-1439.
25. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): A phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009;374(9684):119-125.
26. Laine L, Kivitz AJ, Bello AE, etal. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs ibuprofen alone for reduction of gastric and duodenal ulcer. Am J Gastroenterol 2012;107(3):379-386.
27. Chan FK, Lanas A, Scheiman J, etal. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet 2010;376(9736):173-179.
28. Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: A systematic review and meta-analysis. J Gastroenterol 2013;48(7):830-838.
29. Wang X, Tian HJ, Yang HK, Wanyan P, Peng YJ. Meta-analysis: Cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 2011;23(10):876-880.
30. Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: A randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007;5(10):1167-1174.
31. Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-738.
32. Chan FK. Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gastroenterol Clin North Am 2001;30:937-952.
33. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 2002;359:14-22.
34. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-1418.
35. Malfertheiner P, the European Helicobacter pylori Study Group. Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2, 000 Consensus report. Aliment Pharmacol Ther 2002;16:167-180.
36. Bazzoli F, DeLuca L, Graham DY. Helicobacter pylori infection and the use of NSAIDs. Best Pract Res Clin Gastroenterol 2001;15:775-785.
37. Chan FK, To KF, Wu JC, etal. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with nonsteroidal anti-inflammatory drugs: A randomized trial. Lancet 2002;359:9-13.